Abstract:The (R)-enantiomer of 2-hydroxyglutarate, which is produced when IDH is mutated in human tumours, is shown to stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of HIF and enhanced human astrocyte proliferation. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 have been identified in gliomas, the most common form of brain tumour, and in other cancers including leukaemias. The mutated enzymes produce 2-hydroxyglutarate (2HG), which is a potential oncometabolite. Three papers in this issue of Nature examine the mechanisms through which IDH mutations promote cancers. Lu et al. show that 2HG-producing IDH mutants can prevent the histone demethylation that is required for progenitor cells to differentiate, potentially contributing to tumour-cell accumulation. Turcan et al. show that IDH1 mutation in primary human astrocytes induces DNA hypermethylation and reshapes the methylome to resemble that of the CIMP phenotype, a common feature of gliomas and other solid tumours. Koivunen et al. show that the (R)-enantiomer of 2HG (but not the (S)-enantiomer) can stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of hypoxia-inducible factor (HIF), which in turn can enhance cell proliferation. These papers establish a framework for understanding gliomagenesis and highlight the interplay between genomic and epigenomic changes in human cancers. The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation1. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG)2,3. Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.

Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway

Altered Expression Levels of Idh2 Are Involved in the Development of Colon Cancer

IDH2, a Novel Target of OGT, Facilitates Glucose Uptake and Cellular Bioenergy Production Via NF-κB Signaling to Promote Colorectal Cancer Progression

IC261, a Specific Inhibitor of CK1δ/ε, Promotes Aerobic Glycolysis Through P53-Dependent Mechanisms in Colon Cancer

The Regulatory Mechanisms and Inhibitors of Isocitrate Dehydrogenase 1 in Cancer

Wild-type IDH2 Protects Nuclear DNA from Oxidative Damage and is a Potential Therapeutic Target in Colorectal Cancer.

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

Abstract 3737: Mutant Isocitrate Dehydrogenase Driven Metabolic Reprogramming Results in Therapeutic Vulnerability to Lactate Dehydrogenase Inhibition

Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2)

Isocitrate Dehydrogenase 2 Suppresses The Invasion Of Hepatocellular Carcinoma Cells Via Matrix Metalloproteinase 9

SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases

Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.

Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect

Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

D-2-hydroxyglutarate is Essential for Maintaining Oncogenic Property of Mutant IDH-containing Cancer Cells but Dispensable for Cell Growth